Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The first patients have been dosed in Dynogen Pharmaceuticals' phase II proof of concept trial of its drug DDP733 in patients with constipation-predominant irritable bowel syndrome.
Subscribe to our email newsletter
This DDP733 phase II trial is a randomized, blinded, placebo controlled study that is enrolling patients with the disorder at multiple centers in Canada and is assessing safety and pharmacodynamic efficacy as well as symptom-based endpoints.
DDP733 is an oral, locally acting, prokinetic compound that has shown a favorable safety and efficacy profile in preclinical and clinical studies.
“The initiation of this phase II trial is a significant accomplishment for two reasons – it is Dynogen’s first product candidate to enter a human proof of concept study and we were able to achieve this important milestone within three years of operation as a company,” said Dr Lee Brettman, chief executive officer at Dynogen. “We expect to rapidly advance our product pipeline in the coming months with the initiation of a number of additional significant clinical trials.”